Clinical trials: Diabetes Complications
Wolfram Syndrome
AMX0035 in Adult Patients With Wolfram Syndrome
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
- Trial name
- NCT05676034
- Testing
- AMX0035
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive, double-blind, placebo-controlled, parallel-group…
- Trial name
- NCT01968668
- Testing
- BAY94-8862, BAY 94-8862
- Where
- 16 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Bayer
Abscess, Wound Infection
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the…
- Conditions
- Abscess, Wound Infection, Diabetic Foot, Ulcer
- Trial name
- NCT00402727
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- Where
- 123 sites in Austria, Belgium and 18 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Advanced Renal Cell Carcinoma
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
- Trial name
- NCT04522323
- Testing
- MEDI5752, Axitinib, Lenvatinib
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Chronic Kidney Disease, Type 2 Diabetes
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
This is an observational study, in which data from the past of people with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FLAMINGO (NCT05640180)
- Testing
- Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
- Where
- United States
- Volunteers
- 17,847 people
- Sponsor
- Bayer
Diabetic Foot Ulcer
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers (NTCDU)
The goal of this multi-center,randomized, placebo controlled, evaluator-blinded study is to assess the efficacy and safety of NOX1416 in the treatment of chronic, non-healing, diabetic foot ulcers (DFUs).
- Trial name
- NTCDU (NCT06020664)
- Testing
- NOX-1416+SOC
- Where
- 6 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NOxy Health Products, LLC
Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal…
- Conditions
- Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
- Trial name
- QRX-3 in CKD (NCT06948292)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Ebima Clifford Okundaye
Diabetic Foot Ulcers
Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers
Diabetic foot ulcers are a challenge to health care professionals because there are only few effective topical therapeutic interventions.
- Trial name
- NCT00770939
- Testing
- Vivostat PRF
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Vivostat
Diabetic Foot Ulcer
Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot…
- Trial name
- REBOUND (NCT06420245)
- Testing
- Orion TM Amniotic Membrane Allograft, Standard of Care (SOC)
- Where
- 8 sites in United States
- Volunteers
- 240 people
- Sponsor
- Legacy Medical Consultants
Diabetic Retinopathy
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
This study will assess the safety, tolerability, and pharmacokinetics (PK) of intravitreal (IVT) injections of RO7663498 in participants with diabetic retinopathy (DR).
- Trial name
- CENOTE (NCT07588100)
- Testing
- RO7663498
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Diabetic Foot Ulcer
Treatment of Diabetic Foot Ulcers With AUP1602-C
This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.
- Trial name
- NCT04281992
- Testing
- AUP1602-C
- Where
- 2 sites in Germany, Poland
- Volunteers
- 26 people
- Sponsor
- Aurealis Oy
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FINEROD (NCT06278207)
- Testing
- Finerenone (BAY 94-8862)
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Venous Ulcer, Foot Ulcer, Diabetic
Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers
This study will compare the proportion of patients who have wound closure within 12 weeks as well as the time to wound closure in patients receiving Artacent™ versus standard of care for treatment of non-healing lower extremity…
- Trial name
- TMArtacent (NCT02838784)
- Testing
- Artacent Human Amniotic Membrane, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Tides Medical
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Diabetic Foot Ulcer
Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers
The purpose of the following prospective, randomized, controlled clinical trial is to compare synthetic hybrid-scale fiber matrix (Restrata®, Acera Surgical, Inc.) with standard of care in treating diabetic foot ulcers in human…
- Trial name
- NCT04918784
- Testing
- Restrata®, Wound Dressing
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Acera Surgical, Inc.
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-North (NCT01217476)
- Testing
- Trafermin 0.01% spray
- Where
- 37 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 207 people
- Sponsor
- Olympus Biotech Corporation
Weight Reduction
Avoiding Diabetes After Pregnancy Trial
The Avoiding Diabetes After Pregnancy Trial (ADAPT) study was designed to test the effectiveness of interventions that potentially increase the adoption of Diabetes Prevention Program (DPP) elements by women who had a pregnancy…
- Trial name
- ADAPT (NCT01923350)
- Testing
- Weight Reduction Intervention, Weight Reduction Control Arm, Tested for diabetes
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Social & Scientific Systems Inc.
Painful Diabetic Neuropathy, Diabetes Mellitus
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
- Trial name
- NCT04786340
- Testing
- Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- WinSanTor, Inc
Diabetes Mellitus, Diabetic Neuropathies
Smart Insoles for Improving Sensation, Balance and Mobility in People With Diabetic Peripheral Neuropathy.
The long-term effects of vibrating insoles on improving gait, balance and peripheral sensation in people with diabetic peripheral neuropathy remain unknown.
- Conditions
- Diabetes Mellitus, Diabetic Neuropathies, Unsteadiness
- Trial name
- Pathfeel (NCT06855420)
- Testing
- Vibration on, Vibration off
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Walk With Path
Diabetes Mellitus, Ulcer Foot
Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People
The study will examine the effectiveness of a decellularized dermal matrix (i.e., DermGEN™) in improving wound healing, quality of life and associated costs of treatment of DFUs in First Nations people living in the Northwestern…
- Conditions
- Diabetes Mellitus, Ulcer Foot, Ulcer Healing, Diabetic Foot Ulcer
- Trial name
- NCT05251480
- Testing
- Standard of Care, DermGEN™
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- DeCell Technologies Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.